conferenceseries.com

7th Annual Conference on

Stem Cell and Regenerative Medicine

August 04-05, 2016 Manchester, Uk

The treatments with a neurogenesis promoting nutraceutical elicit cognitive improvement in a mouse model of Alzheimer's disease

Yung-Feng Liao, Rita P Y Chen and Chang-Jen Huang Academia Sinica, Taiwan

A lzheimer's disease (AD) is a progressive neurodegenerative disease and is the most common form of dementia in the elderly. The lack of disease-modifying therapeutics for AD has imposed a huge social burden. Accumulated evidence has suggested that neurotoxicity elicited by of amyloid- β (A β) and Tau, the two pathological hallmarks of AD, significantly contribute to the pathogenesis and progression of AD. It has been proposed that neurogenic agents with neuroprotective efficacy could be potential therapeutics for AD by reviving the neurogenesis of endogenous neural stem cells to replace the lost neurons in the diseased brain. We thus seek to identify novel neurogenesis-promoting agents from herbal extracts and determine whether herbal extracts effective on inducing neurogenesis can reduce A β -elicited neurotoxicity. An *in vivo* neurogenesis assay is established to perform the primary screen of herbal extracts. Effective herbal extracts are validated by a secondary zebrafish model of tauopathy independently. The *in vivo* efficacy of herbal extract (HE238) that exhibit biological efficacy in promoting *in vivo* neurogenesis and concomitantly suppressing the neurotoxicity elicited by amyloidopathy. Our data show that treatments with HE238 can effectively induce neurite outgrowth and promote the clearance of A β and Tau. Oral administration of HE238 for 2 month also significantly improves the cognitive function in an A β 42-injection mouse model. Together, our data suggest that the active ingredients of HE238 could present an enormous resource for AD-alleviating agents.

Biography

Yung-Feng Liao has completed his PhD from University of Georgia, Athens, GA, USA in 1998 and Postdoctoral studies from Harvard Medical School and affiliated hospitals. He is an Associate Research Fellow of Academia Sinica, a premier research institution in Taiwan. He has published 47 peer-reviewed papers in reputed journals and has been serving as an Editorial Board Member of repute.

yliao@sinica.edu.tw

Notes: